Home・Aktien・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Geschlossen

BrancheGesundheitswesen

5.65 -2.25

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.54

Max

5.77

Schlüsselkennzahlen
By Trading Economics
Einkommen	-21M -24M
Verkäufe	-14M 51M
EPS	-0.07
Gewinnspanne	-47.189
Angestellte	435
EBITDA	-17M -5.2M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+25.43% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-120M 2.2B
Vorheriger Eröffnungskurs	7.9
Vorheriger Schlusskurs	5.65

Nachrichtenstimmung

By Acuity

100%

329 / 340 Ranking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Maravai LifeSciences Holdings Inc (Class A) Prognose

Kursziel

By TipRanks

25.43% Vorteil

12-Monats-Prognose

Durchschnitt 7.25 USD 25.43%

Hoch 8 USD

Tief 6.5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Maravai LifeSciences Holdings Inc (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Maravai LifeSciences Holdings Inc (Class A) – Dist abgegeben haben.

Stimmung

By Acuity

329 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.